Home › Research › Health systems and care delivery
Delayed treatment initiation of oral anticoagulants among Medicare patients with atrial fibrillation
Xuemei Luo, Jakson Roberto Gaeski de Chaves, Amol D. Dhamane, Feng Dai, Dominick Latrémouille-Viau, Aolin Wang. American Heart Journal Plus Cardiology Research and Practice, 2024-02-02
Topic: Risk, prevention and care in population studies
Plain-language summary
= 314,472) as early OAC initiation. Median age for both cohorts was 78 years. In the early and delayed OAC cohorts, 47.1 % and 47.6 % were male and 88.8 % and 86.6 %, were White, respectively. Factors associated with delayed OAC initiation (odds ratio; 95 % confidence interval) included Black race (1.29; 1.25 to 1.33), west region (1.29; 1.26 to 1.32), comorbidities such as dementia (1.27; 1.23 to 1.30), recent bleeding hospitalization (1.22; 1.18 to 1.27), prior authorization (1.69; 1.66 to 1.71), tier 4 formulary for index OAC at AF diagnosis (1.26; 1.22 to 1.30). Our study revealed that nearly one-third of Medicare patients with AF experienced delayed OAC initiation. Key patient characteristics found to be associated with delayed OAC initiation included race and ethnicity, comorbidities, and formulary restrictions.
What this study adds
Evidence grade: Low
This study found that about one-third of Medicare patients with atrial fibrillation started oral anticoagulants late, and that having dementia was among the factors linked to delayed start. It is about stroke-prevention medication timing in atrial fibrillation, not about treating, curing, or preventing Alzheimer's disease.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Luo, X., de Chaves, J. R. G., Dhamane, A. D., Dai, F., Latrémouille-Viau, D., & Wang, A. (2024). Delayed treatment initiation of oral anticoagulants among Medicare patients with atrial fibrillation. American Heart Journal Plus Cardiology Research and Practice. https://doi.org/10.1016/j.ahjo.2024.100369
Vancouver
Luo X, de Chaves JRG, Dhamane AD, Dai F, Latrémouille-Viau D, Wang A. Delayed treatment initiation of oral anticoagulants among Medicare patients with atrial fibrillation. American Heart Journal Plus Cardiology Research and Practice. 2024. doi:10.1016/j.ahjo.2024.100369. PMID: 38510996.
BibTeX
@article{luo2024-38510996,
author = {Luo, Xuemei and de Chaves, Jakson Roberto Gaeski and Dhamane, Amol D. and Dai, Feng and Latrémouille-Viau, Dominick and Wang, Aolin},
title = {{Delayed treatment initiation of oral anticoagulants among Medicare patients with atrial fibrillation}},
journal = {American Heart Journal Plus Cardiology Research and Practice},
year = {2024},
doi = {10.1016/j.ahjo.2024.100369},
pmid = {38510996},
url = {https://doi.org/10.1016/j.ahjo.2024.100369}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Median age for both cohorts was 78 years.
- In the early and delayed OAC cohorts, 47.1 % and 47.6 % were male and 88.8 % and 86.6 %, were White, respectively.
- Factors associated with delayed OAC initiation (odds ratio; 95 % confidence interval) included Black race (1.29; 1.25 to 1.33), west region (1.29; 1.26 to 1.32), comorbidities such as dementia (1.27; 1.23 to 1.30), recent bleeding hospitalization (1.22; 1.18 to 1.27), prior authorization (1.69; 1.66 to 1.71), tier 4 formulary for index OAC at AF diagnosis (1.26; 1.22 to 1.30).
- Our study revealed that nearly one-third of Medicare patients with AF experienced delayed OAC initiation.
- Key patient characteristics found to be associated with delayed OAC initiation included race and ethnicity, comorbidities, and formulary restrictions.
Why it matters
This study found that about one-third of Medicare patients with atrial fibrillation started oral anticoagulants late, and that having dementia was among the factors linked to delayed start. It is about stroke-prevention medication timing in atrial fibrillation, not about treating, curing, or preventing Alzheimer's disease.
Study details
- Evidence strengthLow
How this study scored 31/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (American Heart Journal Plus Cardiology Research and Practice) |
| Journal's citation record | 0 / 4 | American Heart Journal Plus Cardiology Research and Practice: journal h-index 23 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2024 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 4 year(s) since 2024 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Aolin Wang: h-index 23 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Pfizer (United States): institution h-index 832 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 4 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 38510996) |
| Free to read | 2 / 2 | Free to read |
| Total | 31 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1016/j.ahjo.2024.100369
- PubMed: 38510996
- Original source →
- Free full text: American Heart Journal Plus Cardiology Research and Practice →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Health systems and care delivery from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.